



Mednarodni Kompetenčni center za
Medicinsko Konopljo

Globalna Akademija Medicinske Konoplje

Pridruži se naši
akademijski skupnosti

PRVI SEMESTER
24.02. - 19.03.2026

32 študijskih ur, certificiran program,
Nivo Nacionalna strokovna poklicna kvalifikacija,
Priznane Kreditne Točke za Zdravnike Zdravniške zbornice Slovenije

Prevodi posnetkov predavanj angleški - slovenski/slovensko - angleški jezik
Zvočna knjiga predavanj v angleškem jeziku
Priporočeno strokovno gradivo

PROGRAM (slovensko)

Globalna Akademija Medicinske Konoplje ©

Mednarodni Kompetenčni center za Medicinsko Konopljo

PRVI SEMESTER 24.02. – 19.03.2026

**32 študijskih ur, certificiran program,
Nivo Nacionalna strokovna poklicna kvalifikacija,
Priznane Kreditne Točke (32) za Zdravnike Zdravniške zbornice Slovenije**

**Prevodi posnetkov predavanj angleški - slovenski/slovensko - angleški jezik
Zvočna knjiga predavanj v angleškem jeziku
Priporočeno strokovno gradivo**

Cena usposabljanja 1.500,00 € na udeleženca s certifikatom

24.02.2026 (dan 1)

Zgodovina uporabe konoplje v medicinske namene in trendi (3 ure)

Dr. Tina Mele - SLOVENIJA EU

Skozi zgodovino uporabe konoplje v medicinske namene se lahko veliko naučimo o sami rastlini in njenem delovanju; še posebej, ker je bila sredi 20. stoletja zaradi raznoraznih vzrokov preganjana, neželena rastlina in tako nimamo nekih "sodobnih" raziskav, zapisov o njenem delovanju. Vendar pa je bila pred tem zelo cenjena zdravilna rastlina in na prelomu iz 19. v 20. stoletje je bilo o rastlini konoplja objavljenih več 100 znanstvenih člankov, organizirane so bile tudi mednarodne konference na temo uporabe konoplje in iz teh zapisov, podatkov se lahko marsikaj naučimo. Do leta 1941 je bila konoplja kot rastlina vključena tudi v Ameriško farmakopejo (o razlogih, zakaj so jo umaknili še vedno poteka burna debata) in imela uradno potrjene indikacije za njeno uporabo. S ponovnim širjenjem njene uporabe v medicinske namene po svetu, vidimo podobne "vzorke", kot so jih opazovali že v preteklosti. Torej, zgodovina uporabe konoplje v medicinske namene nam lahko zelo veliko pove o tem, kdaj in kako uporabiti konopljo kot celo rastlino v medicinske namene.

25.02.2026 (dan 2)

Mehanizem delovanja konoplje kot cele rastline (3 ure)

Dr. Tina Mele SLOVENIJA EU

Konoplja je veliko več kot le THC in CBD. Uporaba cele rastline napram izoliranim ali sintetičnim učinkovinam prinaša prednosti sinergije in zato je pogosto recimo tudi potreba po psihoaktivnemu THC (ki lahko prinaša s seboj neželene učinke intoksikacije) manjša in je tako uporaba cele rastline bolj varna, kot izoliranih ali sintetičnih učinkovin. Počasi se raziskuje tudi druge kanabinoide in njihove kislinske oblike, terpeene in flavonoide, ki jih konoplja vsebuje in ki prinašajo veliko koristi za naše zdravje.

Pri predpisovanju konoplje kot zdravila ne moremo mimo razumevanja endokanabionidnega sistema, ki je en izmed poglavitnih regulatornih sistemov v našem telesu (pa ga v medicinskih knjigah pogosto ni ne omenjajo), zato si bomo v tem predavanju pogledali delovanje tega sistema in kako nam lahko konoplja kot cela rastlina koristi.

26.02.2026 (dan 3)

Endokanabinoidni sistem (2 uri)

Dr. Tanja Bagar – SLOVENIJA EU

26.02.2026 (dan 3)

Zdravljenje bolnikov z medicinsko konopljo: priložnosti in negotovosti (1 ura)

Dr. Mikael Kowal – NIZOZEMSKA EU

03.03.2026 (dan 4)

Odkritje in delovanje kanabinoidnih receptorjev CB2 (1 ura)

Dr. Philip Blair – ZDRUŽENE DRŽAVE AMERIKE

Nedavne raziskave so potrdile prisotnost funkcionalnih receptorjev CB2 (CB2R) v možganih, kar je izpodbijalo prejšnja prepričanja, da gre le za periferne receptorje. To odkritje odpira nove možnosti za terapevtsko ciljanje pri motnjah osrednjega živčevja.

- Prejšnje študije so nakazovale, da CB2R v možganih niso prisotni, zato so jih označili za periferne receptorje.
- Novi dokazi kažejo, da se CB2R izražajo v mikrogliji in nevronih v različnih možganskih regijah.
- Funkcionalni CB2R so vključeni v nevroinflamatorno delovanje in lahko igrajo vlogo pri zdravljenju motenj osrednjega živčevja.
- Razprava o prisotnosti CB2R v možganih se nadaljuje kljub znatnim dokazom, ki podpirajo njihov obstoj.

03.03.2026 (dan 4)

Terapevtski potencial ciljanja na CB2R (1 ura)

Dr. Philip Blair – ZDRUŽENE DRŽAVE AMERIKE

Ciljanje na CB2R predstavlja obetaven pristop k zdravljenju motenj osrednjega živčevja z manj neželenimi učinki v primerjavi s ciljanjem na CB1R. Ta potencial je še posebej pomemben za stanja, povezana z nevroinflamatorno delovanjem.

- Aktivacija CB2R je povezana z zmanjšanimi neželenimi učinki v primerjavi z aktivacijo CB1R.
- CB2R sodelujejo pri uravnavanju nevroinflamacije, ki je ključni dejavnik pri številnih motnjah osrednjega živčevja.
- Raziskave kažejo, da lahko agonisti CB2R zagotavljajo terapevtske koristi brez opojnih učinkov.
- Vloga CB2R pri različnih motnjah, vključno z anksioznostjo, depresijo in odvisnostjo, je vse bolj prepoznavna.

03.03.2026 (dan 4)

Mehanizmi signalizacije CB2R v CNS (1 ura)

Dr. Philip Blair – ZDRUŽENE DRŽAVE AMERIKE

Signalizacija CB2R vključuje kompleksne poti, ki lahko vplivajo na različne fiziološke in patološke procese v CNS. Razumevanje teh mehanizmov je bistveno za razvoj ciljno usmerjenih terapij.

- Aktivacija CB2R zavira aktivnost adenilil ciklaze in sproži poti MAPK in PI3K-Akt.
- Aktivacija CB2R lahko vodi do različnih izidov, vključno z modulacijo presnove in imunskega odziva.
- CB2R se primarno izražajo postsinaptično in lahko zavirajo postsinaptično nevronske delovanje.
- Inducibilna narava CB2R med vnetjem poudarja njihov potencial kot terapevtskih tarč pri nevroinflamatornih stanjih.

04.03.2026 (dan 5)

CB2R-ECS pri odvisnosti in motnjah uporabe substanc (1 ura)

Dr. Philip Blair – ZDRUŽENE DRŽAVE AMERIKE

ECS, zlasti CB2R, je vpleten v mehanizme odvisnosti in motenj uporabe substanc, vključno z odvisnostjo od alkohola in drog. Ciljno delovanje na CB2R lahko ponudi nove terapevtske strategije za obvladovanje odvisnosti.

04.03.2026 (dan 5)

Cross-talk med mikrobiomom in endokanabinoidnim sisitemom (1 ura)

Dr. Tanja Bagar - SLOVENIJA - EU

04.03.2026 (dan 5)

Kanabinol (CBN) blaži s starostjo povezan kognitivni upad z izboljšanjem zdravja sinaptičnih in mitohondrijskih vezi (1 ura)

Dr. Pamela Maher - ZDRUŽENE DRŽAVE AMERIKE

05.03.2026 (dan 6)

Delovanje in uporaba THC (2 uri)

Dr. Tina Mele - SLOVENIJA – EU

Raziskave se pogosto zaradi "enostavnosti" in ponovljivosti rezultatov osredotočajo na eno samo učinkovino in tako imamo kar nekaj raziskav, podatkov glede delovanja THC in čeprav je rastlina konoplje veliko več kot samo THC, je za razumevanje delovanja nujno poznati tudi, kaj je znanost ugotovila glede samega delovanja THC in njegovih učinkov. Prednosti in slabosti THC oz nevarnosti in previdnostni ukrepi. Kdaj nam THC koristi v pripravkih in kdaj ne.

05.03.2026 (dan 6)

Delovanje in uporaba CBD (2 uri)

Dr. Tina Mele - SLOVENIJA – EU

O CBD, ki je ne-psihoaktivna učinkovina konoplje se največ v znanstvenih krogih govori, ko je govora o določenih oblikah epilepsije, kar je ne samo anedoktalno,

ampak tudi znanstveno potrjeno in tudi v Sloveniji v praksi zelo učinkovito uporabljeno zdravilo oz pripravki.

Ampak CBD ima tudi na drugih področjih, kot je npr. anksioznost ogromen potencial.

Prav tako je na trgu poplava CBD proizvodov, ki je potrebna kritične presoje. CBD deluje na mnogo

10.03.2026 (dan 7)

Interakcije med zdravili in kanabinoidi (1 ura)

Dr. Tanja Bagar - SLOVENIJA – EU

10.03.2026 (dan 7)

Študije preniliranih flavonoidov, terpenov in drugih zdravilnih snovi v Medicinski konoplji (1 ura)

Prof. Dr. Samo Kreft, mag. farm. - SLOVENIJA EU

Predavanje povzema biosintezo in strukture ključnih ne-kanabinoidnih spojin v konoplji. Poudarek je na preniliranih flavonoidih (npr. kanflavini), ki nastajajo po fenilpropanoidsko–flavonoidnih poteh z O- in C-prenilacijo (aromatske preniltransferaze), ter na mono- in seskviterpenih iz poti MEP/MVA. Obravnavamo, kako prenilacija vpliva fizikalno-kemijske in farmakološke lastnosti (lipofilnost, vezavo na membrane in stabilnost) ter povzamemo vpliv obdelave (sušenje, shranjevanje) na profile. Metodološko izpostavimo LC-MS za fenole in GC-MS za hlapne. Težišče je na variabilnosti kemovarjev, standardizaciji in jasni kemijski terminologiji.

10.03.2026 (dan 7)

Kislinski in nekislinski kanabinoidi kot zdravilne snovi v konoplji (1 ura)

Prof. Dr. Samo Kreft, mag. farm. - SLOVENIJA EU

Predavanje obravnava skupino kislinskih in nevtralnih kanabinoidov. CBGA nastane iz olivetolne kisline in GPP; specifične sintaze tvorijo THCA, CBDA, CBCA, ki z dekarboksilacijo preidejo v THC, CBD, CBC. Primerjamo strukture, tautomerijo in možnosti izomerizacije, oksidacijske poti (npr. v kinone) ter stabilnost glede na toploto, svetlobo, kisik in vlago. Opišemo topnost/porazdelitev v oljih proti vodnim matricam, matrične učinke pripravkov in kvantifikacijo z HPLC/LC-MS ob skrbnem

vzorčenju, da se izognemo in-vitro dekarboksilaciji. Poudarek je načelen: razmerja biosinteza–struktura–lastnost, označevanje kislinskih/nevtralnih vsebin in posledice za ponovljivo sestavo.

11.03.2026 (dan 8)

Uporaba medicinske konoplje pri zdravljenju tesnobe (1 ura)

Dr Kylie O'Brien PhD - AVSTRALIJA

11.03.2026 (dan 8)

Vloga CB2R pri psihiatričnih motnjah (1 ura)

Dr. Philip Blair – ZDRUŽENE DRŽAVE AMERIKE

Endokanabinoidni sistem (ECS) in njegov kanabinoidni receptor tipa 2 (CB2R) sta vse bolj prepoznavna zaradi svoje vloge pri različnih psihiatričnih motnjah, vključno z anksioznostjo, depresijo in shizofrenijo. Raziskave kažejo, da bi lahko CB2R služili kot potencialne terapevtske tarče za ta stanja, čeprav so potrebne nadaljnje študije za pojasnitev njihove vloge.

- CB2R se izražajo v možganskih regijah, povezanih z anksioznostjo, kot sta amigdala in hipokampus.
- Študije kažejo, da lahko ligandi CB2R modulirajo anksioznostno podobno vedenje pri živalskih modelih, pri čemer JWH-015 povzroča anksioгене odzive, GW405833 pa kaže anksiolitične učinke.
- Pri modelih depresije se ravni izražanja CB2R razlikujejo, nekatere študije pa kažejo na povečane ravni pri kroničnem blagem stresu (KMS).
- Spremembe v izražanju genov in beljakovin kanabinoida CB2 pri žrtvah samomora
- Raziskave shizofrenije poudarjajo spremenjeno izražanje CB2R kot odziv na materino deprivacijo in izpostavljenost psihostimulantom, kar kaže na potencialno vlogo pri psihotičnih simptomih.

11.03.2026 (dan 8)

Načini pridelave in predelave Medicinske konoplje za zagotavljanje klinične kakovosti (1 ura)

M.Sc. Majda Robić - SLOVENIJA EU

Industrija konoplje prehaja iz črnega na legalni trg, zato sta razvoj izdelkov in metode ekstrakcije postala osrednja točka. Do danes je bilo v rastlini konoplje identificiranih več kot tisoč kemičnih sestavin, ki imajo vse različne kemične lastnosti, za katerih pridelavo in ohranitev so zahtevani visoki standardi, kateri zahtevajo različne pogoje za shranjevanje med sušenjem in ekstrakcijo, v prvi vrsti pa zdrave, čiste in strokovne pridelave brez pesticidov kar je ključno za zdravo in varno uporabo konoplje, kot to zahtevajo specifične posemne bolezni in pacienta.

11.03.2026 (dan 8)

Mednarodno spoznavanje tržišča in poslovanja z medicinsko konopljo (1 ura)

M.Sc. Majda Robić - SLOVENIJA EU

Globalni pregled trga medicinske konoplje je ključen za razumevanje ne samo poslovanja z zdravili ampak tudi za zdravljenje in predpisovanje medicinske konoplje. Svetovni trg medicinske konoplje, ki je bil leta 2024 ocenjen na 21,33 milijarde USD, ki pa naj bi leta 2025 dosegel 27,81 milijarde USD in do leta 2035 dosegel preko 211,54 milijarde USD, kar predstavlja 22,5-odstotno letno stopnjo rasti v napovedanem obdobju, to pa je kapital, ki globoko posega v premike lokalnega in mednarodnega gospodarstva, tržišče ter uvozne strategije ter dobave za namen zdravljenja posamezne države, zdravstva in farmacije, ki pa je pravno še vedno zelo omejeno in specifično.

12.03.2026 – 17.03.2026

Zakon o medicinski konoplji za slovenske zdravnike

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AVSTRALIJA

"Pravni okvir in poklicna odgovornost pri predpisovanju medicinske konoplje: celovit vodnik za slovenske zdravnike" katerega bo predstavil eden izmed mednarodno najvidnejših pravnikov, ki skupaj z mednarodno stroko ustvarja in brani okolje medicinske konoplje, odvetnik Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ

Odvetnik Charles Kovess, bo udeležencem strokovno predval in podučil o ključnih pravnih momentih, katere mora poznati vsak zdravnik na domačem in mednarodnem zdravstvenem poslovnem okolju da:

- Predpisujete medicinsko konopljo v popolni skladnosti s slovensko zakonodajo

- Se izognete odškodninskim zahtevkom zaradi malomarnosti z ustreznim upravljanjem tveganj
- Pridobite in dokumentirate veljavno informirano soglasje
- Ustvarite branljive zdravstvene kartoteke
- Zaplete rešujte z ustreznimi pravnimi odzivi
- Spoznajte mednarodne pravne zapletenosti
- Izpolnite vse regulativne in poročevalske obveznosti

KLJUČNE TEME

- Slovenska zakonodaja o medicinski konoplji po pravnomočnosti referendumске volje Zakona o konoplji za medicinske in znanstvene namene
- Regulativni okviri EU in izdelki, ki jih je odobrila EMA
- Štirje elementi zdravniške malomarnosti in kako jih preprečiti
- Posebne populacije: pediatrična, geriatrična, nosečniška, psihiatrična
- Zahteve glede informirane privolitve, specifične za konopljo
- Standardi dokumentacije in skladnost z GDPR
- Obvladovanje neželenih učinkov: zastrupitev, hiperemeza, motnja uporabe
- Kakovost izdelkov, tveganja kontaminacije in odgovornost
- Mednarodni pravni modeli (Kanada, ZDA, Izrael, Nemčija)
- Vprašanja delovnega, zavarovalniškega in delovnopravnega prava

EDINSTVENO VREDNOSTNO PONUDBO

Ta tečaj edinstveno združuje:

- Pravno znanje mednarodno priznanih odvetnikov
- Praktična uporaba v vsakodnevni klinični praksi
- Vsebina, specifična za Slovenijo, ki temelji na novi nacionalni zakonodaji
- Perspektiva EU za čezmejno razumevanje
- Osredotočenost na obvladovanje tveganj za zaščito zdravnikov pred odgovornostjo z možnostjo pravnega svetovanja v zdravniški stroki
- Pristop, ki temelji na dokazih in mednarodnih izkušnjah

12.03.2026 (dan 9)

Pravni temelji medicinske konoplje v Sloveniji in EU

Pregled novih slovenskih in Evropskih pravnih predpisov, mednarodnih pravnih okvirjev v okolju zdravljenja z medicinsko konopljo *(1 ura)*

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AVSTRALIJA

12.03.2026 (dan 9)

Poklicna odgovornost in dolžnost skrbnega ravnanja v medicini s konopljo

Razumevanje malomarnosti, standarda oskrbe in strategij za preprečevanje odgovornosti *(1 ura)*

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AVSTRALIJA

12.03.2026 (dan 9)

Informirana privolitev in pravice pacientov pri zdravljenju s konopljo

Pravne zahteve za soglasje, avtonomijo pacienta in dokumentacijo *(1 ura)*

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AVSTRALIJA

17.03.2026 (dan 10)

Standardi dokumentacije in pravna obramba

Ustvarjanje pravno utemeljenih zdravstvenih kartotek, ki ščitijo tako pacienta kot zdravnika *(1 ura)*

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AVSTRALIJA

17.03.2026 (dan 10)

Obvladovanje zapletov, neželenih dogodkov in pravnih obveznosti

Obravnavanje zapletov, povezanih s konopljo, obvezno poročanje in odgovornost za izdelek (1 ura)

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AVSTRALIJA

17.03.2026 (dan 10)

Mednarodne 6erspective in prihodnji pravni izzivi

Globalni pravni okviri, čezmejna vprašanja in priprave na regulativni razvoj (1 ura)

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AVSTRALIJA

18.03.2026 (dan 11)

Konzultacije med predavatelji in udeleženci

Strokovna razprava

19.03.2026 (dan 12)

Konzultacije med predavatelji in udeleženci

Strokovna razprava

Ekipa Globalne Akademije Medicinske Konoplje

Medicinske konoplje

Visoka strokovna predavateljica in doktorica medicine

Dr. Kylie O'Brien, dr.

AVSTRALIJA

Profesorica Kylie O'Brien, doktorica kitajske medicine in znanosti (Chin Med), magister javnega zdravja, diplomirana medicinska sestra (Chin Med), diplomirana optometristka, diplomirana specialistka terciarnega izobraževanja.

Kylie, se je prvotno izobraževala kot optometristka, po 15 letih klinične prakse pa se je preusmerila v kitajsko medicino (KM) in si zgradila kariero kot akademikinja na tem področju. Razvila je učne načrte za tri magistrske študije KM in bila koordinatorica tečajev za dodiplomske in magistrske študije KM na Univerzi Victoria. Kasnejše vloge prodekanje (poučevanje in učenje) na Univerzi Victoria, direktorice za ocenjevanje in načrtovanje učenja (Univerza Deakin), nacionalne akademske direktorice (AIAS), direktorice za izobraževanje (Nacionalni inštitut za integrativno medicino) in direktorice za izobraževanje (Avstralazijska fakulteta za prehransko in okoljsko medicino) so ji omogočile poglobljeno razumevanje in močne vodstvene sposobnosti v terciarnem izobraževanju. V industrijo medicinske konoplje je vstopila leta 2018 in postala ena vodilnih avstralskih pedagogov na tem področju. Aktivno sodeluje v kliničnih raziskavah medicinske konoplje in je avtorica treh knjig: O'Brien in Sali, A Clinicians Guide to Integrative Medicine, Springer 2017; O'Brien in Blair, Medicinal Cannabis and CBD in Mental Healthcare, Springer 2021 in O'Brien in Bosak, Medicinal Cannabis in Women's Health, Springer 2025. Je izredna profesorica na Univerzi Torrens in izredna profesorica na NICM Health Research Institute (Univerza v Zahodnem Sydneyju) ter članica strokovnega odbora TEQSA avstralske vlade.

Medicinske konoplje

Visok strokovni predavatelj, doktor medicine

Dr. Philip W. Blair, dr. med.

ZDRUŽENE DRŽAVE AMERIKE

POLKOVNIK Philip Blair, dr. med., je diplomiral na West Pointu leta 1972, se izobraževal iz družinske medicine, služil kot vojaški zdravnik v Zalivski vojni in se po 25 letih upokojil. 15 let je zdravil kompleksne bolezni, od leta 2014 pa zdravi, svetuje in predava o endokanabinoidnem sistemu in nepsihoaktivnem kanabidiolu. [50] Dr. Philip Blair, dr. med. (polkovnik ameriške vojske), je diplomiral na West Pointu leta 1972, bil vojaški zdravnik in se po 25 letih upokojil. 15 let je zdravil kompleksne bolezni, od leta 2014 pa zdravi, svetuje in predava o endokanabinoidnem sistemu in kanabidiolu iz konoplje. O CBD-ju se je posvetoval s pacienti, starši in strokovnjaki po vsem svetu. Leta 2021 je soavtor knjige Zdravilna konoplja in CBD v duševnem zdravstvu ter razvil BCPLus, aktivator CB2R, ki ni iz konoplje. (74 t) Dr. Philip Blair, dr. med. (polkovnik v pokoju ameriške vojske) je družinski zdravnik in svetovalec za obvladovanje bolezni na severozahodu ZDA. Diplomiral je na West Pointu leta 1972 in na Medicinski fakulteti Univerze v Miamiu leta 1978, se izobraževal iz družinske medicine in služil kot bojni zdravnik v zalivski vojni med letoma 1990 in 1991. Po zdravniških nalogah na treh celinah in 25 letih v uniformi se je upokojil iz vojske in se ukvarja s svetovanjem o obvladovanju kompleksnih bolezni. Od leta 2014 dr. Blair preučuje, zdravi, piše in predava o kanabidiolu in naravnem endokanabinoidnem sistemu (ECS) človeškega telesa. Disfunkcija ECS je tesno povezana s celotnim spektrom kroničnih bolezni. Njegov cilj je obnoviti zdravje in zmogljivost z izboljšanjem ECS s prehrano, vadbo, ustreznimi zdravili in nepsihoaktivnimi zelišči. Leta 2021 je soavtor knjige Medicinal Cannabis and CBD in Mental Healthcare (Medicinska konoplja in CBD v duševnem zdravstvu) in razvil BCPLus, peroralni ne-kanabisni aktivator CB2R iz kariofilena. [148 t]

Medicinske konoplje

Visoka profesionalna predavateljica in raziskovalka

Dr. Tina Mele

SLOVENIJA – EU

Dr. Tina Mele, je doktorica veterinarske medicine in doktorica medicinskih znanosti, zeliščarka, modra ženska in ena največjih strokovnjakinj za zeleno naravno medicino in uporabo divje hrane.

Doktorsko disertacijo je zaključila na Medicinski fakulteti, s področja farmakologije. Svoje raziskave o konoplji je predstavila v akademskem članku "Nove indikacije in razvoj zdravil na osnovi konoplje". Dr. Mele dela kot profesorica biopsihologije na Univerzi na Primorskem v Sloveniji. Trenutno raziskuje in predava o strokovnih temah, kot so vključevanje zeliščne medicine v okolje znanosti in tradicije, zeliščna medicina, medicina za ljudi in znanstveni dosežki, ter je strokovna zagovornica tem, povezanih z medicinsko konopljo.

Medicinske konoplje

Visoka profesionalna raziskovalka

Dr. Tanja Bagar

SLOVENIJA - EU

Dr. Tanja Bagar, je direktorica inštituta Icanna in docentka na Alma Mater Europaea - ECM. Diplomirala je iz mikrobiologije in kasneje doktorirala iz biomedicine, s smerjo molekularna biologija in biokemija, ter ima izkušnje s klinično mikrobiologijo, raziskovalno biotehnologijo, ekologijo in poučevanjem. Že vrsto let študentom poučuje mikrobiologijo, biokemijo in druge ekološke teme. Zanima jo, kaj se dogaja v mikroskopskih celicah našega telesa, kako celice sodelujejo in komunicirajo med seboj ter kako zunanji dejavniki vplivajo na naše telo. Od hrane in toksinov do dotika.

Konoplja v medicini je pionirska knjiga dr. Tanje Bagar, ki z avtoriteto uveljavljene znanstvenice na področju biomedicine prepričljivo predstavlja znanstvene temelje uporabe konoplje v medicini, kjer skozi znanstvena dejstva o delovanju telesa na celični ravni tako laikom kot strokovnjakom na visoki ravni pojasnjuje, kako se endokanabinoidni sistem izraža v telesu in tako vpliva na njegovo delovanje s tveganji, varno uporabo in odmerjanjem.

Medicinske konoplje

Visok znanstvenik

Dr. Mikael Kowal

NIZOZEMSKA -EU

Mikael Kowal dela v industriji medicinske konoplje od leta 2014. Pred tem je doktoriral na Univerzi v Leidnu na Nizozemskem na temo psihofarmakologije konoplje. Skozi leta je Mikael sodeloval pri izvajanju več kliničnih preskušanj s konopljo. V zadnjem času

aktivno vzpostavlja interni znanstvenoraziskovalni program. Mikaela zanima raziskovanje celotnega medicinskega potenciala rastline konoplje, hkrati pa se zaveda omejitev in tveganj zdravljenja s konopljo.

Medicinske konoplje

Visoka profesorica za raziskave

Laboratorij za celično nevrobiologijo

Pamela Maher, dr.

ZDRUŽENE DRŽAVE AMERIKE

Pamela Maher je diplomirala na Univerzi McGill v Montrealu v Quebecu in doktorirala na Univerzi Britanske Kolumbije v Vancouvru v Britanski Kolumbiji. Trenutno je raziskovalna profesorica in vodja Laboratorija za celično nevrobiologijo na Inštitutu Salk v La Jolli v Kaliforniji. Njena raziskovalna področja vključujejo modele in mehanizme celične smrti pri staranju in nevrodegenerativnih boleznih s posebnim poudarkom na poti celične smrti, ki jo regulira oksitoza/feroptoza. Poleg tega se ukvarja s karakterizacijo in razvojem naravnih produktov in njihovih derivatov za zdravljenje akutnih in kroničnih nevroloških motenj, vključno z Alzheimerjevo boleznijo.

Dr. Pamela Maher išče spojine, ki bi lahko upočasnile ali ustavile napredovanje nevrodegenerativnih bolezni, s poudarkom na Alzheimerjevi bolezni. Njen nov pristop uporablja spojine, pridobljene iz naravnih produktov, kot so jagode, kurkuma in konoplja, za zdravljenje celičnega staranja in izgube spomina, ki ju opazimo pri Alzheimerjevi bolezni. Maherjeva in njena ekipa sta odkrili novo pot celične smrti, imenovano oksitoza/feroptoza, in sta bili med prvimi, ki so pri odkrivanju zdravil za Alzheimerjevo bolezen upoštevali staranje.

Medicinske konoplje

Visok raziskovalec strokovnega razvoja, farmacevt, fakultetni predavatelj in publicist

Prof. dr. Samo Kreft, magister farmacije

SLOVENIJA - EU

Prof. dr. Samo Kreft je redni profesor na Fakulteti za farmacijo Univerze v Ljubljani, kjer raziskuje zdravilne rastline in druga zdravila naravnega izvora ter o njih predava študentom. Opravljal je tudi strokovne funkcije pri Evropski agenciji za zdravila v Londonu. Objavil je več kot 100 izvirnih znanstvenih člankov v priznanih znanstvenih revijah. Poleg znanstvenih člankov je napisal več kot 70 poljudnih in strokovnih člankov ter je reden gost v televizijskih in radijskih oddajah. Bil je urednik več knjig, kot so Sodobna fitoterapija, ki je bila prodana v že več kot 3000 izvodih; Prehranska dopolnila, ki je izšla pri ugledni tuji založbi Elsevier; Kvakadabra v kuhinji; Ajurveda – nova pot za zdravo življenje v Evropi.

Zanimajo ga zdravilne rastline, predvsem konoplja, saj se v njih prepletajo raziskovalna področja botanike, kemije, ekologije, medicine, pa tudi etnologije in zgodovine. Fascinirajo ga zabrisane meje med raziskanim in neraziskanim, preverjenim in tradicionalnim, uradnim in alternativnim. Je urednik spletne strani [SODOBNA FITOTERAPIJA](#).

Medicinske konoplje in industrijske konoplje

Visoka profesionalna NVO lobistka, Mednarodna predlagateljica zakona, Globalni javni zagovornik Prava javnega interesa in Strateški vodja globalnih projektov

M.Sc. Majda Robić

SLOVENIA – EU

Pred Evropskim Parlamentom, Evropsko Komisijo in Združenimi narodi ter pred številnimi veleposlaništvimi, gospa Robić Majda, kot mednarodna lobistka in zastopnica NVO in vodja Slovenskih, Evropskih in mednarodnih projektov, med drugim neodvisno zagovarja pomen industrijske konoplje, kanabinoidov in medicinske konoplje, v enakovrednem in strokovnem interesu. S svojo delovno ekipo dosega ključne preboje in globalne dosežke, ki predstavljajo ključen prispevek k globalnemu razvoju, gospodarstvu ter zdravju ljudi in okolja tudi pred 60 držav Združenih narodov – UN, kjer vodi globalna pogajanja in NVO lobiranje za medicinsko konopljo in CBD, kjer z ekipo 2023, dosežejo dokončen ključen zavezujoč globalen dogovor.

V Sloveniji vodi Nacionalni delovni tim za konopljo Republike Slovenije, ki je pod njenim vodstvom uvedel zakonodajo za trženje, razvoj in proizvodnjo izdelkov iz industrijske konoplje in je strokovno sodelovala pri vzpostavitvi Zakona o konoplji za medicinske in znanstvene namene (ZKMZN).

Že več kot 15 let je predsednica Društva zeliščarjev Pomurje v javnem interesu na področju kmetijstva in je izvršna direktorica WORLD HEMP CONGRESS, ter GLOBAL medicinal cannabis INNOVATIONS, GLOBAL HEMP INNOVATION, GLOBAL HEMP tech INNOVATON, GLOBAL HEMP food INNOVATION, ter GLOBAL green tech INNOVATIONS, ter upravlja Panonia Institut, kjer vodi PROJEKTNO RAZVOJNO MREŽO in druge aktualne razvojne projekte.

M.Sc. Majda Robić, je na mednarodnem magistrskem nivoju zaključila MicroMasters Certified International Master in EMA - Podjetniški um v akciji v digitalni dobi, ki potrjuje njeno izobrazbo na področju inovacij, vodenja in priprave mednarodnih zahtevnih projektov in je na magistrskem nivoju poklicno orientirana na Poslovno pravo in lobiranje v EU, Evropsko pravo, Pravo in človeške vire, Mednarodne gospodarske odnose in institucije ter druga širša poslovna vodstvena razvojna znanja. Svoje znanje nadgrajuje na Stanford Business University v ZDA in pripravlja doktorat iz Politike in Diplomacije v Švici.

Medicinske konoplje in industrijske konoplje

Visoki mednarodni odvetnik

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ

AVSTRALIJA

G. Charles Kovess je z odliko diplomiral iz prava na Univerzi v Melbournu in kasneje magistriral iz prava na Univerzi Monash, v pravnem svetu pa se je uveljavil kot pomembna osebnost. Njegovo strokovno znanje in vodstvo sta dosegla vrhunec z ustanovitvijo lastne odvetniške pisarne in kasneje kot vodja oddelka za gospodarsko pravo pri Barker Gosling v Avstraliji, kjer se je kasneje specializiral za pravo medicinske in industrijske konoplje ter svetoval organizacijam, ki si želijo širiti svet. Od predsedovanja Avstralsko-madžarski gospodarski zbornici do prispevkov k različnim dobrodelnim organizacijam je njegova zavezanost pozitivnemu globalnemu vplivu neomajna, prav tako pa tudi njegova zavezanost sektorju konoplje, kjer sodeluje pri pripravi avstralske in mednarodne zakonodaje na tem področju, razvoju inovacij in vključevanju konoplje v gospodarsko in družbeno življenje Avstralije in sveta. Trenutno je predsednik Avstralskega združenja za industrijsko konopljo, član izvršnega odbora Zveze mednarodnih organizacij za konopljo ter neprecenljiv član in strokovni predavatelj in svetovalec na SVETOVNEM KONGRESU O KONOPLIJI.

Kovess, danes med drugim predstavlja enega najvidnejših svetovnih javnih promotorjev in motivatorjev za poslovanje, razvoj, etične zadeve in naložbe, kjer dela v nedavno ustanovljenem podjetju svetovnega formata Kovess International.

ODGOVORNI ORGANIZATOR:


Društvo zeliščarjev Pomurje, NVO v javnem interesu

Pomurje Herbalists Association, NGO in the public interest

Rakičan, Lendavska 3, 9000 Murska Sobota SI-EU

E: Drustvo.Zeliscarjev.Pomurje@gmail.com

E: WORLD.HEMP.CONGRESS@gmail.com



PROGRAM (English)

Global Medicinal Cannabis Academia ©

International Medical Cannabis Competence Center

FIRST SEMESTER 24.02. – 19.03.2026

**32 study hours, certified program,
Level National Professional Qualification,
Recognized Credit Points (32) for Doctors of the Medical Chamber of Slovenia**

**Translations of lecture recordings English - Slovenian / Slovenian - English
Audiobook of lectures in English**

Recommended professional materials

Training price € 1,500.00 per participant with certificate

24.02.2026 (day 1)

History of Cannabis Use for Medical Purposes and Trends (3 hours)

Dr. Tina Mele - SLOVENIA EU

Through the history of the use of cannabis for medical purposes, we can learn a lot about the plant itself and its effects; especially since in the mid-20th century it was persecuted as an unwanted plant for various reasons and so we do not have any "modern" research or records about its effects. However, before that, it was a highly valued medicinal plant and at the turn of the 19th and 20th centuries, more than 100 scientific articles were published about the cannabis plant, international conferences were also organized on the topic of the use of cannabis and we can learn a lot from these records and data. Until 1941, cannabis was also included as a plant in the United States Pharmacopeia (the reasons why it was removed are still hotly debated) and had officially confirmed indications for its use. With the resurgence of its use for medicinal purposes around the world, we are seeing similar "patterns" as those observed in the past.

So, the history of cannabis use for medicinal purposes can tell us a lot about when and how to use cannabis as a whole plant for medicinal purposes.

25.02.2026 (day 2)

Mechanism of Action of Cannabis as a Whole Plant (3 hours)

Dr. Tina Mele SLOVENIA EU

Cannabis is much more than just THC and CBD. Using the whole plant compared to isolated or synthetic active ingredients brings the advantages of synergy and therefore often the need for psychoactive THC (which can bring with it the side effects of intoxication) is lower and the use of the whole plant is therefore safer than isolated or synthetic active ingredients. Other

cannabinoids and their acid forms, terpenes and flavonoids, which cannabis contains and which bring many benefits to our health, are also being slowly researched.

When prescribing cannabis as a medicine, we cannot ignore understanding the endocannabinoid system, which is one of the main regulatory systems in our body (but it is often not mentioned in medical books), so in this lecture we will look at the functioning of this system and how cannabis as a whole plant can benefit us.

26.02.2026 (day 3)

Endocannabinoid System (2 hours)

Dr. Tanja Bagar – SLOVENIA EU

26.02.2026 (day 3)

Treating Patients with Medical Cannabis: Opportunities and Uncertainties (1 hour)

Dr. Mikael Kowal – NETHERLANDS EU

03.03.2026 (day 4)

Discovery and Function of CB2 Cannabinoid Receptors (1 hour)

Dr. Philip Blair – UNITED STATES OF AMERICA

Recent research has confirmed the presence of functional CB2 receptors (CB2Rs) in the brain, challenging previous beliefs that they were only peripheral receptors. This discovery opens new avenues for therapeutic targeting in CNS disorders.

- Previous studies suggested CB2Rs were absent in the brain, labeling them as peripheral receptors.
- New evidence shows CB2Rs are expressed in microglia and neurons in various brain regions.
- Functional CB2Rs are involved in neuroinflammation and may play a role in treating CNS disorders.
- The debate over the presence of CB2Rs in the brain continues despite substantial evidence supporting their existence.

03.03.2026 (day 4)

Therapeutic Potential of Targeting CB2Rs (1 hour)

Dr. Philip Blair – UNITED STATES OF AMERICA

Targeting CB2Rs presents a promising approach for treating CNS disorders with fewer adverse effects compared to CB1R targeting. This potential is particularly relevant for conditions associated with neuroinflammation.

- CB2R activation is linked to reduced adverse effects compared to CB1R activation.
- CB2Rs are involved in regulating neuroinflammation, which is a key factor in many CNS disorders.
- Research indicates that CB2R agonists may provide therapeutic benefits without intoxicating effects.
- The role of CB2Rs in various disorders, including anxiety, depression, and addiction, is being increasingly recognized.

03.03.2026 (day 4)

Mechanisms of CB2R Signaling in the CNS (1 hour)

Dr. Philip Blair – UNITED STATES OF AMERICA

CB2R signaling involves complex pathways that can influence various physiological and pathological processes in the CNS. Understanding these mechanisms is essential for developing targeted therapies.

- CB2R activation inhibits adenylyl cyclase activity and initiates MAPK and PI3K-Akt pathways.
- The activation of CB2Rs can lead to diverse outcomes, including modulation of metabolism and immune response.
- CB2Rs are primarily expressed post-synaptically and can inhibit postsynaptic neuronal function.
- The inducible nature of CB2Rs during inflammation highlights their potential as therapeutic targets in neuroinflammatory conditions.

04.03.2026 (day 5)

CB2R-ECS in Addiction and Substance Use Disorders (1 hour)

Dr. Philip Blair – UNITED STATES OF AMERICA

The ECS, particularly CB2Rs, is implicated in the mechanisms of addiction and substance use disorders, including alcohol and drug addiction. Targeting CB2Rs may offer new therapeutic strategies for managing addiction.

04.03.2026 (day 5)

Cross-talk between the Microbiome and the Endocannabinoid System (1 hour)

Dr. Tanja Bagar - SLOVENIA - EU

04.03.2026 (day 5)

Cannabinol (CBN) Ameliorates Age-Related Cognitive Decline by Improving the Health of Synaptic and Mitochondrial Connections (1 hour)

Dr. Pamela Maher UNITED STATES OF AMERICA

05.03.2026 (day 6)

The Action and Use of THC (2 hours)

Dr. Tina Mele - SLOVENIA - EU

Research often focuses on a single active ingredient due to "simplicity" and reproducibility of results, and so we have quite a bit of research and data on the action of THC, and although the cannabis plant is much more than just THC, to understand its action it is also necessary to know what science has found out about the action of THC itself and its effects. Advantages and disadvantages of THC or dangers and precautions. When is THC beneficial to us in preparations and when is it not.

05.03.2026 (day 6)

The Action and Use of CBD (2 hours)

Dr. Tina Mele - SLOVENIA – EU

CBD, which is a non-psychoactive active ingredient of cannabis, is most often discussed in scientific circles when it comes to certain forms of epilepsy, which is not only anecdotal, but also a scientifically confirmed and very effectively used medicine or preparations in Slovenia.

But CBD also has enormous potential in other areas, such as anxiety. There is also a flood of CBD products on the market that need critical assessment. CBD works in many ways

10.03.2026 (day 7)

Drug-Cannabinoid Interactions (1 hour)

Dr. Tanja Bagar - SLOVENIA - EU

10.03.2026 (day 7)

Studies of Prenylated Flavonoids, Terpenes and Other Medicinal Substances in Medical Cannabis (1 hour)

Prof. Dr. Samo Kreft, mag. pharm. - SLOVENIA EU

Studies of Prenylated Flavonoids, Terpenes and Other Medicinal Substances in Medical Cannabis

This lecture outlines the biosynthetic origins and structures of key non-cannabinoid constituents in cannabis. We focus on prenylated flavonoids (e.g., cannflavins) formed via phenylpropanoid–flavonoid pathways with O- and C-prenylation by aromatic prenyltransferases, and on mono-/sesquiterpenes arising from MEP/MVA pathways. We discuss how prenylation modulates physico-chemical, pharmacological properties (lipophilicity, membrane affinity, stability), and summarize processing effects (drying, storage) on profiles. Methods include LC-MS for phenolics and GC-MS for volatiles. Emphasis is on chemovar variability, standardization, and clear chemical nomenclature.

10.03.2026 (day 7)

Acidic and non-acidic cannabinoids as medicinal substances in cannabis (1 hour)

Prof. Dr. Samo Kreft, mag. pharm. - SLOVENIA EU

We examine the chemical system of acidic vs. neutral cannabinoids. CBGA arises from olivetolic acid + GPP; dedicated synthases yield THCA, CBDA, CBCA, which undergo decarboxylation to THC, CBD, CBC. The talk compares structures, tautomerism and isomerization risks, oxidation pathways (e.g., to quinones), and stability under heat, light, oxygen, moisture. We review partitioning/solubility in oils vs. aqueous media, matrix effects in preparations, and practical quantification by HPLC/LC-MS with attention to sample handling to avoid in-vitro decarboxylation. The emphasis is conceptual: biosynthesis–structure–property relationships, labeling that distinguishes acidic/neutral content, and implications for reproducible composition.

11.03.2026 (day 8)

The use of medical cannabis in the treatment of anxiety (1 hour)

Dr. Kylie O'Brien PhD – AUSTRALIA

In this presentation, Professor O'Brien will discuss how the endocannabinoid system (ECS) is involved in the regulation of stress and emotions, what changes occur in the ECS in anxiety, and why medicinal cannabis might be useful in treating anxiety. The scientific evidence base, including preclinical research and human research investigating the effectiveness/efficacy of medicinal cannabis and several of its key components in anxiety will be explored.

11.03.2026 (day 8)

Role of CB2Rs in Psychiatric Disorders (1 hour)

Dr. Philip Blair - UNITED STATES OF AMERICA

The endocannabinoid system (ECS) and its cannabinoid receptor type 2 (CB2R) are increasingly recognized for their involvement in various psychiatric disorders, including anxiety, depression, and schizophrenia. Research indicates that CB2Rs may serve as potential therapeutic targets for these conditions, although further studies are needed to clarify their roles.

- CB2Rs are expressed in brain regions associated with anxiety, such as the amygdala and hippocampus.
- Studies show that CB2R ligands can modulate anxiety-like behaviors in animal models, with JWH-015 inducing anxiogenic responses and GW405833 showing anxiolytic effects.
- In depression models, CB2R expression levels vary, with some studies indicating increased levels in chronic mild stress (CMS) conditions.
- Alterations in Gene and Protein Expression of Cannabinoid CB2 in Suicide Victims
- Schizophrenia research highlights altered CB2R expression in response to maternal deprivation and psychostimulant exposure, indicating a potential role in psychotic symptoms.

11.03.2026 (day 8)

Methods of cultivation and processing of medical cannabis to ensure clinical quality

(1 hour)

M.Sc. Majda Robić - SLOVENIA EU

The cannabis industry is transitioning from the black market to the legal market, so product development and extraction methods have become a central focus. To date, more than a thousand chemical compounds have been identified in the cannabis plant, all with different chemical properties, the production and preservation of which require high standards, which require different storage conditions during drying and extraction, and first and foremost, healthy, clean and professional cultivation without pesticides, which is key to the healthy and safe use of cannabis, as required by the specifics of the individual disease and patient.

11.03.2026 (day 8)

International introduction to the medical cannabis market and business (1 hour)

M.Sc. Majda Robić - SLOVENIA EU

A global overview of the medical cannabis market is essential for understanding not only the pharmaceutical business but also the treatment and prescription of medical cannabis. The global medical cannabis market, estimated at USD 21.33 billion in 2024, is expected to reach USD 27.81 billion in 2025 and exceed USD 211.54 billion by 2035, representing a 22.5% annual growth rate over the forecast period, is a capital that deeply affects the movements of the local and international economy, the market and import strategies and supplies for the purpose of treatment of an individual country, healthcare and pharmaceuticals, which is still legally very limited and specific.

05.02.2026 – 10.02.2026

Medical Cannabis Act for Slovenian Doctors

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA

"Legal Framework and Professional Responsibility in Prescribing Medical Cannabis: A Comprehensive Guide for Slovenian Doctors" will be presented by one of the most prominent international lawyers who, together with the international profession, creates and defends the medical cannabis environment, attorney Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ. Attorney Charles Kovess, will expertly present and educate participants on the key legal points that every physician in the domestic and international healthcare business environment must know in order to:

- Prescribe medical cannabis in full compliance with Slovenian law
- Avoid negligence claims with appropriate risk management
- Obtain and document valid informed consent
- Create defensible medical records
- Resolve complications with appropriate legal responses
- Understand international legal complexities
- Meet all regulatory and reporting obligations

KEY TOPICS

- Slovenian legislation on medical cannabis, after the referendum will of the Cannabis for Medical and Scientific Purposes final Act
- EU regulatory frameworks and EMA-approved products
- The four elements of medical negligence and how to prevent them
- Special populations: pediatric, geriatric, pregnancy, psychiatric
- Cannabis-specific informed consent requirements
- Documentation standards and GDPR compliance
- Management adverse effects: poisoning, hyperemesis, use disorder
- Product quality, contamination risks and liability
- International legal models (Canada, USA, Israel, Germany)
- Labor, insurance and employment law issues

UNIQUE VALUE OFFER

This course uniquely combines:

- Legal knowledge from internationally recognized lawyers
- Practical application in everyday clinical practice
- Slovenia-specific content based on new national legislation
- EU perspective for cross-border understanding
- Focus on risk management to protect physicians from liability with the possibility of legal advice in the medical profession
- An approach based on evidence and international experience Legal foundations of medical cannabis in Slovenia and the EU

12.03.2026 (day 9)

Overview of new Slovenian and European legal regulations

International legal frameworks in the environment of medical cannabis treatment (1 hour)

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA

12.03.2026 (day 9)

Professional responsibility and duty of care in medical cannabis

Understanding negligence, standard of care and strategies for preventing liability (1 hour)

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA

12.03.2026 (day 9)

Informed consent and patient rights in cannabis treatment

Legal requirements for consent, patient autonomy and documentation (1 hour)

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA

17.03.2026 (day 10)

Documentation Standards and Legal Defense

Creating Legally Sound Medical Records That Protect Both Patient and Physician (1 hour)

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA

17.03.2026 (day 10)

Managing Complications, Adverse Events, and Legal Liabilities

Addressing Cannabis-Related Complications, Mandatory Reporting, and Product Liability (1 hour)

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA

17.03.2026 (day 10)

International Perspectives and Future Legal Challenges

Global Legal Frameworks, Cross-Border Issues, and Preparing for Regulatory Development (1 hour)

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ – AUSTRALIA

18.03.2026 (day 11)

Consultations between lecturers and participants

Expert discussion

19.03.2026 (day 12)

Consultations between lecturers and participants

Expert discussion

Global Medicinal Cannabis Academia Team

Medicinal Cannabis

Senior Professional lecturer & Doctor of Medicine

Dr. Kylie O'Brien, PhD

AUSTRALIA

Professor Kylie O'Brien is, Doctor of Chinese Medicine and Science (Chin Med), MPH, BAppSc(Chin Med), BSc(Optomety), Grad Cert Tertiary Education.

Trained originally as an optometrist, after 15 years in clinical practice Kylie career-changed to Chinese medicine (CM), developing a career as an academic in CM. She developed the curricula for three Master degrees in CM, and was the Course Coordinator for Victoria University's undergraduate and Western Sydney University Masters courses in CM. Subsequent roles as Associate Dean (Teaching and Learning) at Victoria University, Director of Assessment and Learning Design (Deakin University), National Academic Director (AIAS), Director of Education (National Institute of Integrative Medicine) and Director of Education (Australasian College of Nutritional and Environmental Medicine) equipped her with a deep understanding and strong leadership skills in tertiary education. She entered the medicinal cannabis industry in 2018 and became one of Australia's leading educators in this field. She is actively involved in clinical research into medicinal cannabis, and has authored three books: O'Brien and Sali, A Clinicians Guide to Integrative Medicine, Springer 2017; O'Brien and Blair, Medicinal Cannabis and CBD in Mental Healthcare, Springer 2021 and O'Brien and Bosak, Medicinal Cannabis in Women's Health, Springer 2025. She is an Adjunct Professor at Torrens University and an Adjunct Associate Professor at NICM Health Research Institute, (Western Sydney University) and is a member of the Australian government's TEQSA Expert Panel.

Medicinal Cannabis

Senior Professional lecturer Doctor of Medicine

Dr. Philip W. Blair PhD

UNITED STATES OF AMERICA

COL Philip Blair, MD, graduated from West Point '72, trained in Family Medicine, served as a combat physician in Gulf War and retired after 25 years. He managed complex diseases for 15 years and since 2014 he has been treating, consulting and lecturing on the endocannabinoid system and nonpsychoactive cannabidiol. [50] Dr. Philip Blair, MD, (Colonel USArmy) graduated from West Point '72, was a combat physician and retired after 25 years. He managed complex diseases for 15 years and since 2014 has treated, consulted and lectured on the endocannabinoid system and cannabidiol from hemp. He has consulted with patients, parents and professionals worldwide about CBD. In 2021 he coauthored the Medicinal Cannabis and CBD in Mental Healthcare and developed BCPLus, a non-cannabis CB2R activator. (74w) Dr. Philip Blair, MD, (Colonel USArmy retired) is a Family Physician and consultant in disease management in the Northwest. He graduated from West Point 1972 and University of Miami School of Medicine 1978, trained in Family Medicine and served as combat physician in 1990-1991 Gulf War. After medical assignments in three continents and 25 years in uniform he retired from the Army and has been consulting on complex disease management. Since 2014 Dr. Blair has been studying, treating, writing and lecturing about cannabidiol and the human body's natural endocannabinoid system (ECS). ECS dysfunction appears closely associated with the full range of chronic illness. His goal is to restore health and performance by enhancing the ECS through diet, exercise, appropriate medications and non-psychoactive herbs. In 2021 he coauthored the Medicinal Cannabis and CBD in Mental Healthcare and developed BCPLus, an oral non-cannabis CB2R activator from caryophyllene. [148w]

Medicinal Cannabis

Senior Professional Lecturer & Researcher

Dr. Tina Mele

SLOVENIA – EU

Dr. Tina Mele, is a Doctor of Veterinary Medicine and Doctor of Medical Sciences, an herbalist, a wise woman and one of the greatest experts in green natural medicine and the use of wild food. Dr. Mele, completed her doctoral dissertation at the Faculty of Medicine, in the field of Pharmacology. She presented her research on cannabis in the academic article "New indications and development of Cannabis - based medicines". Dr. Mele works as a professor of Biopsychology at the University of Primorska in Slovenia. She currently researches and lectures on professional topics such as the integration of herbal medicine in the environment of science and tradition, herbal medicine, medicine for people and scientific achievements, and she is a professional advocate for topics related to medical cannabis.

Medicinal Cannabis

Senior Professional Researcher

Doc. Dr. Tanja Bagar

SLOVENIA - EU

Dr. Tanja Bagar, is the director of the Icanna Institute and an assistant professor at Alma Mater Europaea - ECM. She graduated in microbiology and later received a PhD in Biomedicine, majoring in Molecular Biology and Biochemistry, and has experience in clinical microbiology, research biotechnology, ecology, and teaching. She has been teaching microbiology and biochemistry and other ecological topics to students for many years. She is interested in what happens in the microscopic cells of our body, how cells cooperate and communicate with each other, and also how external factors affect our body. From food and toxins to touch. Cannabis in Medicine is a pioneering book by Dr. Tanja Bagar, with the authority of an established scientist in the field of biomedicine, convincingly presents the scientific foundations of the use of cannabis in medicine, where, through scientific facts about the functioning of the body at the cellular level, she explains to both laypeople and high-level professionals how the endocannabinoid system is expressed in the body and thus influences its functioning through risks, safe use and dosage.

Medicinal Cannabis

Senior Scientist

PhD Mikael Kowal

NETHERLANDS -EU

Mikael Kowal, has been working in the medicinal cannabis industry since 2014. He previously completed his PhD at Leiden University in the Netherlands on the topic of psychopharmacology of cannabis. Over the years Mikael has been involved in the conduct of several clinical trials with cannabis. More recently, he has been actively setting up an internal scientific research

program. Mikael is interested in exploring the full medical potential of the cannabis plant, while acknowledging the limitations and risks of treatment with cannabis.

Medicinal Cannabis

Senior Research Professor

Cellular Neurobiology Laboratory

Pamela Maher, PhD

UNITED STATES OF AMERICA

Pamela Maher, received her BSc from McGill University in Montreal, Quebec and her PhD from the University of British Columbia in Vancouver, British Columbia. She is currently a Research Professor and head of the Cellular Neurobiology Laboratory at The Salk Institute in La Jolla, CA. Her research interests include models and mechanisms of cell death in aging and neurodegenerative diseases with a specific focus on the oxytosis/ferroptosis regulated cell death pathway. In addition, she works on the characterization and development of natural products and derivatives thereof for the treatment of acute and chronic neurological disorders including Alzheimer's disease. Dr. Pamela Maher is searching for compounds that could slow or stop the progression of neurodegenerative diseases, with a focus on Alzheimer's disease. Her novel approach uses compounds derived from natural products such as strawberries, turmeric, and cannabis to treat the cellular aging and memory loss seen in Alzheimer's disease. Maher and her team discovered a new cell death pathway called oxytosis/ferroptosis and were among the first to consider aging in the discovery of drugs for Alzheimer's disease.

Medicinal Cannabis

Senior Professional Development Researcher, Pharmacist, Faculty Lecturer and Publicist

Prof. Dr. Samo Kreft, Master of Pharmacy

SLOVENIA - EU

Prof. Dr. Samo Kreft is a full professor at the Faculty of Pharmacy of the University of Ljubljana, where he researches medicinal plants and other medicines of natural origin and lectures on them to students. He has also held professional positions at the European Medicines Agency in London. He has published more than 100 original scientific articles in renowned scientific journals. In addition to scientific articles, he has written more than 70 popular and professional articles and is a regular guest on television and radio shows. Dr. Kreft was the editor of several books, such as *Sodobna fitoterapija*, which has already sold more than 3,000 copies; *Food supplements*, which was published by the reputable foreign publishing house Elsevier; *Kvarkadabra in the kitchen*; *Ayurveda – a new way for healthy life in Europe*. He is interested in medicinal plants, primarily cannabis, because they intertwine the research fields of botany, chemistry, ecology, medicine, as well as ethnology and history. He is fascinated by the blurred boundaries between the researched and the unexplored, the proven and the traditional, the official and the alternative. He is the editor of the website [MODERN PHYTOTHERAPY](#).

Medicinal Cannabis & Hemp

Senior Professional NGO lobbyist, international law proponent, global public interest law advocate and strategic leader of global projects

M.Sc. Majda Robić

SLOVENIA – EU

Before the [European Parliament](#), the [European Commission](#) and the [United Nations](#), as well as before numerous embassies, [Ms. Robić Majda](#), as an international lobbyist and NGO representative and head of Slovenian, European and international projects, among other things, independently advocates for the importance of industrial hemp, cannabinoids and medical cannabis, in equal and professional interest. With her work team, she achieves key breakthroughs and global achievements that represent a key contribution to global development, economy and human and environmental health, also before 60 countries of the [United Nations - UN](#), where she leads global negotiations and NGO lobbying for medical cannabis and CBD, where with the 2023 team, they reach a final key binding global agreement. In Slovenia, she leads the National Cannabis Working Team of the Republic of Slovenia, which, under her leadership, introduced legislation for the marketing, development and production of industrial hemp products and professionally participated in the establishment of the Cannabis for Medical and Scientific Purposes Act (ZKMZN). For more than 15 years, she has been the president of the [Pomurje Herbalists' Association](#) in the public interest and is the executive director of [WORLD HEMP CONGRESS](#), [GLOBAL medicinal cannabis INNOVATIONS](#), [GLOBAL HEMP INNOVATION](#), [GLOBAL HEMP tech INNOVATION](#), [GLOBAL HEMP food INNOVATION](#) and [GLOBAL green tech INNOVATIONS](#), and manages the [Panonia Institute](#)

where she leads the PROJECT DEVELOPMENT NETWORK and other current projects. M.Sc. Majda Robić, at the international master's level, completed the MicroMasters Certified International Master in EMA - Entrepreneurial Mind in Action in the Digital Age, which confirms her education in the field of innovation, management and preparation of international demanding projects and at the master's level, she is professionally oriented in Business Law and Lobbying in the EU, European Law, Law and Human Resources, International Economic Relations and Institutions and other broader business management development knowledge. He is upgrading his knowledge at Stanford Business University in the USA and is preparing for a doctorate in Politics and Diplomacy in Switzerland.

Medicinal Cannabis & Hemp

Senior international Lawyer

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ

AUSTRALIA

Mr. Charles Kovess, graduated with honours in Law from the University of Melbourne and later obtained a Master of Laws from Monash University, has established himself as a formidable figure in the legal world. His expertise and leadership culminated in the establishment of his own law firm and later as head of the commercial law department at Barker Gosling in Australia, later specialising in medical and industrial cannabis law, and also advising organisations seeking to expand globally. From chairing the Australian-Hungarian Chamber of Commerce to contributing to various charities, his commitment to positive global impact is unwavering, as is his commitment to the cannabis sector, where he is involved in drafting Australian and international legislation in the field, developing innovation and embedding cannabis into the economic and social life of Australia and globally. He is currently the President of the Australian Industrial Hemp Association, a member of the Executive Committee of the Federation of International Hemp Organizations and an invaluable member and expert at the WORLD HEMP CONGRESS.

Kovess, today, among other things, represents one of the most prominent global business, development, ethical and investment public promoters and motivators, where he works in the recently world-class company Kovess International.

RESPONSIBLE ORGANIZER:

Društvo zeliščarjev Pomurje, NVO v javnem interesu

Pomurje Herbalists Association, NGO in the public interest

Rakičan, Lendavska 3, 9000 Murska Sobota SI-EU

E: Drustvo.Zeliscarjev.Pomurje@gmail.com

E: WORLD.HEMP.CONGRESS@gmail.com